Author Year of publication Study
design 		PT Materials and methods Outcome measures
LARA Donor site Membrane NOI LOP
(months) 		IS
(%) 		SS
(%) 		PIMBL Two-dimensional Histomorphometric
Mean (SD)/range (mm) Mean (SD)/range (mm)
GARW RAA TBV/NB NMB
Antoun et al. [18] 2001 Parallel 12 13 Mandibular symphysis e-PTFE: 5 5 6 100 NR NR 3.7 (SD 1.8) 0.3 (SD 0.4)a NR
None: 8 8 2.9 (SD 1.4) 2.3 (SD 1)
Heberer et al. [33] 2009 Split-mouth 14 33 Iliac crest Bio-Gide®: 17 92 3 100 NR NR NR 1 (range 0.3 to 3.4)b 3 months
48 (range 5 to 94) 29 (range 1 to 52)
None: 16 1 (range 0.4 to 2.1) 43 (range 3 to 98)c 26 (range 2 to 63)
Moussa et al. [34] 2016 Parallel 12 13 Maxilla palate PRF: 7 NR 4 NR NR NR 2.7 (SD 0.7)d 0.8 (SD 0.6)e NR
None: 6 2.1 (SD 0.8) 1.7 (SD 0.8)
Meijndert et al. [35] 2005 Parallel 10 10 Mandibular symphysis Bio-Gide®: 5 10 20 100 100 NR 3.4 (SD 1.1) NR 3 months
57.2 (SD 11.5) 42.3 (SD 11.5)
None: 5 3 (SD 1) 55.2 (SD 6.8) 44.8 (SD 6.8)
Meijndert et al. [36] 2017 Parallel 62 62 Mandibular symphysis Bio-Gide®: 31 62 120 93.5 87.9 0.5 (SD 1.2) NR NR NR
None: 31 100

a(P = 0.001), b(P = 0.38), c(P = 0.46), d(P = 0.138), e(P = 0.006).
e-PTFE = expanded polytetrafluoroethylene; GARW = gain alveolar ridge width; IS = implant survival; LARA = lateral alveolar ridge augmentation; LOP = length of observation period; NB = new bone; NMB = new mineralized bone; NOI = number of implants; NR = not reported; PRF = platelet rich fibrin; PT = number of patients at baseline; RAA = resorption augmented area; SD = standard deviation; SS = suprastructure survival; TBV = total bone volume.